GlassScriptPhysician profile
Seela Ramesh
NPI 1184849630
$2,524.56
in general payments reported to CMS, 2019-2025
26 companies · $955 in 2025
The $955 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $39.76 · 2021: $17.47 · 2022: $312 · 2023: $343 · 2024: $711 · 2025: $955.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,009.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,008.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,014.93 | 2019-2025 | |
| Janssen Biotech, INC. | $180.49 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $156.64 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $152.64 | 2024 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.90 | 2023-2025 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $124.25 | 2025 | Terlivaz |
| Intuitive Surgical, INC. | $92.61 | 2025 | |
| Genzyme Corporation | $84.01 | 2022-2025 | |
| Pfizer INC. | $80.54 | 2022-2025 | |
| Henry Schein, INC. | $64.60 | 2022 | |
| Gilead Sciences, INC. | $52.07 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.11 | 2025 | Entyvio |
| Nestle Healthcare Nutrition INC. | $45.85 | 2022 | |
| Ardelyx, INC. | $39.62 | 2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $38.63 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $36.25 | 2020-2023 | Aemcolo, Talicia |
| Ipsen Biopharmaceuticals, INC | $29.99 | 2025 | Iqirvo |
| Evoke Pharma, INC. | $29.76 | 2022-2023 | Gimoti |
| Ucb, INC. | $25.24 | 2019 | |
| Braintree Laboratories, INC. | $21.34 | 2023 | Suflave |
| Regeneron Healthcare Solutions, INC. | $20.92 | 2023 | Dupixent |
| Medtronic, INC. | $17.47 | 2021 | |
| Covidien LP | $11.61 | 2019 | |
| Qol Medical, LLC | $8.09 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seela Ramesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.